admin@transcom.net

+44 (0)1189 150189

This Company Wants to Rewrite the Future of Genetic Disease—Without Crispr Gene Editing

0 Comments

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

Powered by WPeMatico